Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
Hangzhou-based Unike Biopharma has completed an angel financing round worth tens of millions of RMB, giving the young biotech fresh capital to advance a broad pipeline of long-acting protein and peptide therapeutics built around its proprietary ZT…
AIPher Raises ~RMB 100 Million Angel Round to Build AI-Native Drug Discovery Platform
Chinese AI-driven drug discovery startup AIPher has completed an angel financing round of approximately RMB 100 million (about $14 million+), an unusually large early-stage raise completed just over a month after the company was established. The…
ALLYRNA Raises Over RMB 100 Million to Advance RNA Epigenetics-Based Cancer Drug Pipeline
Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for…
Convergen Closes $15 Million Financing to Advance Novel Protein Degradation Therapies for Neurodegenerative Diseases
Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for…
DAJO Bio Raises Tens of Millions of RMB in Seed Financing to Advance Next-Generation TCR Protein Therapies
Shenzhen-based biotechnology startup DAJO Bio (“DAJO”) has completed a seed financing round worth tens of millions of RMB, providing fresh capital to advance its next-generation T-cell receptor (TCR) protein therapeutic platforms and pipeline…
Navi Therapeutics raises Series A to advance AI-driven next-generation ADC platform
China-based biotech Navi Therapeutics (Shanghai) Co., Ltd. (“Navi”) has completed a Series A financing round, marking the company’s second fundraising since its founding roughly 18 months ago and bringing its cumulative funding to…
MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…
Hopstem completes nearly 200 million yuan Series C financing to accelerate its core iPSC programs.
On August 10, 2026, Zhejiang Hopstem Biotechnology Co., Ltd. (or Hopstem) announced the completion of the first tranche of its nearly RMB 200 million Series C financing. This round of financing was jointly participated in by new shareholders Tasly…
Xgene secured RMB 250 million in series D financing to develop novel non-opioid analgesic drugs
Recently, Xgene Pharmaceutical Inc. (“Xgene”), a company focusing on the research and development of innovative drugs in the fields of pain and neurology, completed a RMB 250 million Series D financing round. This round was jointly led by Yifeng…